Objective: To monitor the adverse drug reactions (ADRs) of atypical antipsychotic drugs in the outpatient department (OPD) of psychiatry in Silchar Medical College and Hospital (SMCH) of Assam, and also to fi nd out the causality and severity of ADRs, related to the antipsychotic drugs. Methodology: It was a prospective observational study carried in OPD of psychiatry. Permission from the institutional ethical committee (SMCH) was obtained. Patients with any psychotic disorder above 18 years (excluding pregnant women) of either sex who were prescribed only one atypical antipsychotic were included. Prescription containing conventional antipsychotics was excluded. ADRs reported spontaneously by the patients and also responses obtained in a questionnaire related to the likely ADRs from the patients was recorded in the case record form. Results: Total 78 patients out of whom 48 males and 30 females were included in this study. Of these, 71 patients complained of different types of problems after taking the medicines. Incidence of ADRs was higher in male (46 patients [64.78%]) in comparison to female (25 patients [35.21%]). Total 31 different types of ADRs were detected with the use of these antipsychotics. Weight gain was the most common ADR observed in 38 patients (53.52%). Out of four atypical antipsychotic drugs which have been encountered during our study causing ADRs, olanzapine was commonest followed by risperidone and amisulpride. Causality assessment using Naranjo's scale revealed that 85 (51.20%) ADRs were found to be "probable" and 81 (48.79%) were found as "possible" ADRs. According to Hartwig's severity assessment scale majority of ADRs were assessed as mild (108 [65.06%]) and 58 (34.93%) ADRs were assessed as moderate. Conclusion: Study showed weight gain was the commonest ADR with atypical antipsychotic drugs. The commonest drug causing ADRs was olanzapine. Majority of ADRs were assessed as probable as per Naranjo's scale and mild according to Hartwig's severity assessment scale.
Introduction
A noxious and unintended response that occurs at drug doses that is usually used in man for treatment, prophylaxis, or diagnosis of a disease or for alteration of physiological function is called an adverse drug reaction (ADR). [1] ADRs are common medication associated adverse events encountered in healthcare facilities all over the world. [2] Adverse events are any unpleasant medical occurrence associated with the use of a drug in humans whether or not considered drug related. [3] Other types of medication associated adverse events include therapeutic failures and adverse drug withdrawal events. [2] Unexpected adverse reactions are those that are not consistent with applicable product information or characteristics of drug. [3] A serious adverse event or reaction is any unpleasant medical occurrence at any dose resulting in the death of the patient or one that is life threatening, demands hospitalisation, or the prolongation of existing hospitalisation and which results in persistent or signifi cant disabilities or incapacities. [4] Th e science and activities relating to the detection, assessment, understanding, and prevention of adverse eff ects, or any other medication related problems is defi ned as pharmacovigilance. Pharmavigilantes are the professionals engaged in pharmacovigilance, which is an integral part of drug therapy and it is slowly gaining importance in our country as more numbers of ADR monitoring centres are developing under the Pharmacovigilance Programme of India (PvPI). [2, 5] About fi ve per cent hospitalisations all over the world are due to ADRs, which present sometimes with fatal symptoms leading to death. [6] Th e second generation or "atypical" antipsychotic medications are the most widely used antipsychotic drugs in psychiatric practice because the fi rst generation or conventional or "typical" antipsychotics are associated with ISSN 2394 -2053 (Print) ISSN 2394 -2061 (Online) www.ojpas.org poor effi cacy against negative symptoms and are associated with unwanted extrapyramidal signs and symptoms (EPS). Particularly at higher doses these typical antipsychotics commonly show bizarre body movements like Parkinsonism, rigidity, and tremors. [7] [8] [9] Currently available atypical antipsychotics are clozapine, olanzapine, risperidone, quetiapine, amisulpride, aripiprazole, zotepine, ziprasidone, asenapine, sertindole, paliperidone. Th ese agents are used in various types of psychiatric manifestations including schizophrenia and they have shown to improve quality of life, have better medication compliance, decrease suicidal tendencies, and depression in these patients. [10] [11] [12] [13] In cases of schizophrenia these agents have shown remarkably lower incidence of EPS and signifi cantly reduce both positive and negative symptoms of schizophrenia. In spite of showing decreased incidence of EPS in schizophrenic patients, these atypical antipsychotic agents vary in their formulations, effi cacy, tolerability, biochemistry, receptor binding site, and spectrum of ADRs like weight gain, tremor, insomnia, and gastrointestinal (GI) upset. [14] [15] [16] Th erefore, for achieving a successful treatment in patients with diff erent psychiatric manifestations healthcare professionals have to detect and assess ADRs of atypical antipsychotic drugs and report, if any to PvPI which aft er analysing shall forward the data to Uppsala ADR monitoring in Sweden for signal generation. ADR reports from psychiatric units are very less. [17] To protect the population on antipsychotic medications from avoidable harm, assessment of ADRs in psychiatric department can play a vital role by detecting ADRs and alerting the physicians to the possibility and circumstances of such events.
Th ere is a defi nite lack of Indian studies on pharmacovigilance activities in mental health sector. Hence, the present study was conducted to evaluate the surveillance of ADRs of atypical antipsychotic drugs in the department of psychiatry in a tertiary care hospital of Assam. 
Methodology
Th is is a prospective observational study in the OPD of psychiatry in SMCH for a period of six months from June 2015 to November 2015. Permission from the institutional ethical committee (SMCH) was taken. Newly diagnosed patients and patients who had not taken any antipsychotic medication for last one month and patients above 18 years with any psychotic disorder irrespective of sex (pregnant women were excluded) who were prescribed single atypical antipsychotic drug were included. Consent for the study was taken from the patients or their relatives. Prescriptions containing conventional or typical antipsychotics and combination of antipsychotics were excluded. Patients were examined when they came for fi rst scheduled revisit or aft er one month whichever was earlier. 
Results
Total 78 patients enrolled in our study. Out of which, seven patients who did not show any signs and symptoms of ADRs even aft er three months of monitoring period were excluded from the study. Of the remaining 71 patients, 46 (64.78%) were male and 25 (35.21%) were female, and prescribed atypical antipsychotic medications were olanzapine, risperidone, amisulpride, and quetiapine. Two patients with violent behaviour were hospitalised. It was later found out and confi rmed that they had those problems due to the nonadherence with the treatment schedule prescribed by the psychiatrists and not because of any medication related event. Same treatment was restarted for both the violent patients and discharged aft er four days with improvement. Every eff ort was done to follow up the patients in monthly schedule. Follow up was done maximum up to four months and was successfully completed to each and every patient. Out of all of ADRs, weight gain, GI upset, insomnia, sedation, aggressive behaviour, and anxiety accounted for nearly 64% of the events (Table 2 ).
Mild to moderate ADRs included headache, tremor, concentration diffi culty, fatigue, anaemia, dizziness, constipation, restlessness, EPS, asthenia, and were treated by changing the dose and/or relevant medications to treat the symptoms. Discontinuation of medication was required for olanzapine due to weight gain in three patients, and for risperidone due to EPS in two patients. Causality assessment ADR: Adverse drug reaction using Naranjo's scale revealed that 85 (51.20%) events were found to be "probable" and 81 (48.79%) were found to be "possible" ADRs ( Table 3) . As per Hertwig's adverse drug severity scale 108 events were assessed as mild followed by 58 events that were assessed as moderate.
Discussion
Atypical antipsychotics are considered as the fi rst-line agents for the treatment of specifi c psychotic disorders. Psychiatrists have been preferring these drugs because of their better treatment effi cacy, better tolerability, and reduced risk of EPS. In spite of effi cacy, tolerability, and reduced risk of EPS there are several types of ADRs which can occur because of these antipsychotic agents. So, the prevention of ADRs can be done by collecting reliable information about their frequencies and possibilities of their risk factors. [20] Th e major drawback of pharmacovigilance system is under reporting. It is due to the lack of awareness at both the level of healthcare professionals and patients. Th e most common method used in pharmacovigilance is the spontaneous reporting and it is the best method to generate signals on new and sometimes rare ADRs of established drugs.
Present study was undertaken for assessment of ADRs of atypical antipsychotic drugs and it was based on active surveillance through questionnaire in addition to the ADRs spontaneously reported by patients or detected by consultants. In the study we found that during initial visits of the patients, the spontaneous reporting of ADR was very less. Th ey were restricted to those ADRs that were very troublesome and uncomfortable to them. It may also be due to the initial or early relief of psychotic signs and symptoms encountered by the patients. We also observed that aft er giving an exposure to specifi c questionnaire related to probable ADRs the spontaneous reporting rate increased. We recorded total 166 ADRs in 71 prescriptions and we can say that active surveillance is very eff ective in reporting of ADRs.
In this study, we tried to make a relationship between the ADR with the dose and duration of treatment with the particular drug. Few ADRs required comparison with previous status and the present status in the same patient. With olanzapine we encountered diff erent kinds of ADRs where GI upset, sleep disturbances (insomnia), sedation, and aggressive behaviour were more frequently observed in the initial course of treatment (within two to three months aft er treatment), while weight gain, EPS, tremor, headache, anxiety were observed on long term (more than three months) use of olanzapine.
Olanzapine is initially started with 5 mg/day and the dose is gradually increased up to maximum of 20 mg/day. All the ADRs encountered were at the dose range of 10-15 mg/day. Weight gain accounted with olanzapine, risperidone, as well as with amisulpride was about 23% of total ADRs. Weight gain is considered clinically signifi cant if it exceeds seven per cent of the initial weight aft er ten weeks. [7, 8, 21] In this study, the mean age for the weight gain was 36 years. We observed that 14 out of 31 weight gainers with olanzapine occurred within a short term (three to four months) and 17 cases on long term (more than four months) use. With risperidone, four out of six weight gains were seen in short duration and two on long duration. Th e weight gain with amisulpride were seen only on long term use.
With risperidone, sedation, anxiety, GI upset, and tremor were observed in the initial (two to three months) course of treatment, while weight gain, EPS, anorexia, fatigue, leg muscle cramp were observed aft er long-term (more than four months) use. Risperidone was given at a dose of 2-6 mg per day and all ADRs with risperidone were observed at the same dose. Most common ADR we encountered with risperidone was weight gain (75%) followed by sedation (62.5%). Weight gain with risperidone was alarmingly high among all of the antipsychotic drugs. EPS were seen in two out of eight patients with risperidone which was about 25% and were managed by reducing the dose and by adding a central anticholinergic drug. We have seen that uses of amisulpride were very common in patients with schizophrenia in psychiatric practice. It may be due to better tolerability and decreased incidence of intolerable side eff ects in psychiatric patients. It is used 200-400 mg per day depending on the severity of the psychiatric illness. We recorded seven patients with amisulpride and noticed non-serious adverse events like GI upset, insomnia, and anxiety commonly. Hypersalivation which is an anticholinergic side eff ect seen in a patient who was on amisulpride only. All ADRs with amisulpride were seen aft er two to three months suggesting that initial period with this drug is relatively safe.
We encountered only two patients with quetiapine during our monitoring period in OPD and both the patients tolerated the drug very well. ADRs noted were headache, somnolence, dry mouth, burning sensation on sole, dizziness, confusion, and blurred vision. It was prescribed as 50 mg per day dose. Th ese ADRs had not aff ected the day to day life of the patients and were seen aft er the third month of starting treatment.
Whatever patients we have encountered with psychotic illness in OPD, maximum patients were from low socioeconomic status. Only a few were from well to do families who can give better treatment and care to the patients, to motivate continuous adherence with the antipsychotic drugs, and to follow up the patient regularly with proper investigation suggested by the psychiatrist. Low level of education is also a major factor which plays an important role in the outcome of these patients. Improper hygiene, lower nutritional status, and social discriminating factor along with poor communication may add to the increase amount of ADRs seen with these patients. 
Limitations
We did not include indoor patients and patients who were receiving more than one antipsychotic medications. As our study had outpatient based design, so the routine examination of blood, urine, electrolyte level, liver function test, kidney function test, or echocardiography (ECG) screening of patients or blood sugar level, lipid and prolactin estimation were diffi cult to obtain. A recent study from this part of the globe has shown elevated prolactin in olanzapine users. [22] Conclusion Th e antipsychotic medications used from early times have been associated with many ADRs. Atypical antipsychotics are used in diff erent types of psychotic disorders including schizophrenia, bipolar disorder, and non-specifi c psychosis.
With discovery of these atypical antipsychotics, ADRs have been reduced to a great extent. Th is study shows that olanzapine is associated with maximum number of ADRs followed by risperidone. Th ese documented ADR reports and the results may be helpful for the future researchers regarding the ADRs of these second generation antipsychotic drugs. With this exercise awareness on pharmacovigilance is inculcated on the healthcare professionals and the patients are also sensitised.
